← 返回

黑色素瘤和鳞状细胞癌 TIL 区室的转录评估揭示耗竭与功能性 T 细胞的意外谱系

英文原题:A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells.

查看英文原题

A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells.

PubMed 2023/10/30(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

基于免疫表型数据的生物信息学整合与网络分析,我们提出了用于恢复黑色素瘤抗肿瘤免疫应答的意料之外的治疗靶点。

中文摘要

为研究与终末耗竭T细胞相关的机制,我们从大体积黑色素瘤中分选同时表达耗竭标志PD-1和TIM-3的CD8+TIL(肿瘤浸润淋巴细胞),并进行转录谱分析。此外,还开展免疫表型分析和功能验证(包括单细胞水平分析),以识别其功能障碍表型的潜在机制。

我们在CD8+PD-1+TIM-3+细胞中发现了TIL领域尚未得到充分研究的新型失调通路,包括胆汁酸和过氧化物酶体相关代谢,以及哺乳动物雷帕霉素靶蛋白(mTOR)信号通路;这些通路与免疫检查点受体表达高度相关。讨论:基于免疫表型数据的生物信息学整合及网络分析,我们提出了可能出乎意料的治疗靶点,以恢复黑色素瘤患者针对肿瘤的免疫应答。

展开英文摘要原文

To investigate mechanisms associated with terminally exhausted T cells, we sorted and performed transcriptional profiling of CD8 + tumor-infiltrating lymphocytes (TILs) co-expressing the exhaustion markers PD-1 and TIM-3 from large-volume melanoma tumors. We additionally performed immunologic phenotyping and functional validation, including at the single-cell level, to identify potential mechanisms that underlie their dysfunctional phenotype.

We identified novel dysregulated pathways in CD8 + PD-1 + TIM-3 + cells that have not been well studied in TILs; these include bile acid and peroxisome pathway-related metabolism and mammalian target of rapamycin (mTOR) signaling pathways, which are highly correlated with immune checkpoint receptor expression. DISCUSSION: Based on bioinformatic integration of immunophenotypic data and network analysis, we propose unexpected targets for therapies to rescue the immune response to tumors in melanoma.

论文信息

作者
Cameron CM、Richardson B、Golden JB、Phoon YP、Tamilselvan B、Pfannenstiel L、Thapaliya S、Roversi G
第一作者单位
Department of Nutrition, Case Western Reserve University, Cleveland, OH, United States.United States
通讯作者单位
Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, United States.United States
期刊
Frontiers in oncology2023
原文标识
PubMed 38023136 · DOI 10.3389/fonc.2023.1200387